Voyager Therapeutics (VYGR) Receivables - Other (2019 - 2026)

Voyager Therapeutics has disclosed Receivables - Other across 8 years of filings, most recently posting $151000.0 for Q1 2026.

• Receivables - Other for Q1 2026 came in at $151000.0, down 68.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $151000.0 (down 68.99% YoY), and the FY2025 annual result was $151000.0, down 77.66% from the prior year.
• Receivables - Other came in at $151000.0 for Q1 2026 at Voyager Therapeutics, roughly flat from $151000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $3.7 million in Q3 2024 to a low of $151000.0 in Q2 2022.
• The 5-year median for Receivables - Other is $676000.0 (2024), against an average of $1.3 million.
• Across the five-year window, Receivables - Other slumped 91.41% in 2022 and soared 2118.54% in 2023, its largest moves.
• Voyager Therapeutics' Receivables - Other stood at $257000.0 in 2022, then jumped by 1200.0% to $3.3 million in 2023, then tumbled by 79.77% to $676000.0 in 2024, then tumbled by 77.66% to $151000.0 in 2025, then changed by 0.0% to $151000.0 in 2026.
• The last three Receivables - Other figures came in at $151000.0 (Q1 2026), $151000.0 (Q4 2025), and $851000.0 (Q3 2025), per Business Quant data.